Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
Sarah Knispel, Maximilian Gassenmaier, Alexander M. Menzies, Carmen Loquai, Douglas B. Johnson, Cindy Franklin, Ralf Gutzmer, Jessica C. Hassel, Carsten Weishaupt, Thomas Eigentler, Bastian Schilling, Patrick Schummer, Judith Sirokay, Felix Kiecker, C. Owen, Maria Isabel Fleischer, Christopher Cann, Katharina C. Kähler, Peter Mohr, Leonie Bluhm, Dennis Niebel, Kai-Martin Thoms, Simone M. Goldinger, Lydia Reinhardt, Friedegund Meier, Carola Berking, Raphael Reinhard, Laura Susok, Paolo A. Ascierto, Konstantin Drexler, Claudia Pföhler, Julia K. Tietze, Lucie Heinzerling, Elisabeth Livingstone, Selma Ugurel, Georgina V. Long, Andreas Stang, Dirk Schadendorf, Lisa Zimmer
Topics & Concepts
MedicineMelanomaImmune checkpointOncologyInternal medicineCancer researchNivolumabImmunotherapyImmune systemImmunologyCancer Immunotherapy and BiomarkersCancer, Hypoxia, and MetabolismImmunotherapy and Immune Responses